153 related articles for article (PubMed ID: 29935046)
1. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods.
Omar H; Said M; Eletreby R; Mehrez M; Bassam M; Abdellatif Z; Hosny A; Megawer S; El Amir M; Yosry A
Clin Transplant; 2018 Aug; 32(8):e13334. PubMed ID: 29935046
[TBL] [Abstract][Full Text] [Related]
2. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
4. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
5. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.
Fahmy DM; Shokeir M; El Zeiny SM; Jonas MM; Abdallah A
J Pediatr; 2021 Apr; 231():110-116. PubMed ID: 33347957
[TBL] [Abstract][Full Text] [Related]
6. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals.
Alswat K; Al-Sohaibani F; Khathlan A; Bashmail A; Alanazi M; Kurdi A; Almakadma AH; Al-Hamoudi W
Ann Saudi Med; 2022; 42(2):89-95. PubMed ID: 35380056
[TBL] [Abstract][Full Text] [Related]
7. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.
El-Garem H; AbdAllah M; Omar H; Cordie A; Abdel Alem S; Mohey Eldin Elzahry MA; Ghaith D; Abou El-Soud NH; Kamal W; Elsharkawy A; Esmat G
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):693-698. PubMed ID: 31043104
[No Abstract] [Full Text] [Related]
8. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
[TBL] [Abstract][Full Text] [Related]
9. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
[TBL] [Abstract][Full Text] [Related]
10. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
[TBL] [Abstract][Full Text] [Related]
11. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
[TBL] [Abstract][Full Text] [Related]
12. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
[TBL] [Abstract][Full Text] [Related]
13. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
[TBL] [Abstract][Full Text] [Related]
14. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.
Abdelbary MS; Samir R; El-Nahaas SM; Shahin RMH; El-Sayed M; Gaber Y; Tantawi O; Zayed NA; Yosry A
J Clin Exp Hepatol; 2022; 12(5):1276-1284. PubMed ID: 36157140
[TBL] [Abstract][Full Text] [Related]
16. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C.
Crespo G; Lens S; Gambato M; Carrión JA; Mariño Z; Londoño MC; Miquel R; Bosch J; Navasa M; Forns X
Am J Transplant; 2014 Feb; 14(2):375-83. PubMed ID: 24410892
[TBL] [Abstract][Full Text] [Related]
17. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
Kawagishi N; Suda G; Kimura M; Maehara O; Yamada R; Tokuchi Y; Kubo A; Kitagataya T; Shigesawa T; Suzuki K; Ohara M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Sakamoto N
Sci Rep; 2021 Apr; 11(1):9207. PubMed ID: 33911145
[TBL] [Abstract][Full Text] [Related]
18. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.
Mölleken C; Ahrens M; Schlosser A; Dietz J; Eisenacher M; Meyer HE; Schmiegel W; Holmskov U; Sarrazin C; Sorensen GL; Sitek B; Bracht T
Clin Mol Hepatol; 2019 Mar; 25(1):42-51. PubMed ID: 30449076
[TBL] [Abstract][Full Text] [Related]
20. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
